Clinical characteristics
SARS-CoV-2 infection, NRS
DISEASE, SARS-COV-2 INFECTION
There were included in the study 109 women (63%) and 64 men (37%). The mean age was 47.8 (SD 1.2) years. The race of the patients was Caucasian in89% and 9.8% Hispanic. A proportion of 15.6% (27 patients) suffered previous COVID-19 with a mean time elapsed to enrolment in the study of 14.2 (1.7) months. The vaccine against SARS-CoV-2 was administered to 159 patients (91.9%) with a mean of 6.3 (0.3) months from the last vaccination dose to study entry. Differences between domperidone and placebo groups in demographics, BMI and previous SARS-CoV-2 infection data were not found (Demographic, baseline physical exam and previous SARS-CoV-2 infection in the study groups.SD: standard deviation.In relation to severity of COVID-19, 166 patients (96%) presented with mild disease, 4 (2.4%) with moderate disease and 3 (1.7%) were asymptomatic. The distribution of patients according to severity of disease was similar in the two study groups, being in the domperidone and placebo group, respectively, 3 (3.4%) and 0 (0%) no asymptomatic patients, 82 (94.3%) and 84 (99.7%) patients with mild disease, and 2 (2.3%) and 2 (2.3%) patients with moderate disease.Results of physical examination were similar in the two study groups (Symptoms observed at baseline: frequency and severity (0–10 points of a NRS) compared by study group.A total of 102 patients (59%) were receiving treatment for medical conditions at inclusion in the study. No significant differences between the study groups were observed in the administration of concomitant medications (Compliance of the study treatment was 97% with no significant differences between the study groups.The viral load was homogeneous between the study groups, with a mean (SD) Ct value of 21.3 (0.4) for ORF1ab, 21.5 (0.4) for N Protein and 27.5 (0.6) for S Protein. The percentages of patients with low, medium and high viral loads were 3.4%, 20.7% and 75.9% for the domperidone group and 4.7%, 14% and 81.4% for the placebo group.